Q-omics provides the consensus-scored LINC02693 profile across patient tissues and cancer cell-line models. LINC02693 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC02693 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, LINC02693 RNA expression shows 19,412 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where LINC02693 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02693 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02693 survival associations across molecular data types. LINC02693 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02693 RNA expression–survival associations across cancer types. High LINC02693 expression shows unfavorable associations in MESO, UCEC, BLCA, THCA and LIHC, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LINC02693 RNA expression.
This table summarizes LINC02693 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02693. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02693 shows lower tumor expression in KIRC, UCEC and THCA and higher tumor expression in HNSC, COAD and KIRP. The HNSC box plot shows higher LINC02693 RNA expression in tumor versus normal tissue (log2 FC = +1.021, t-test p < 0.001).
This table shows molecular features associated with LINC02693 in patient tissues and cancer cell lines. In patient samples, LINC02693 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC02693 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
